Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 2, 1999, Pages 1128-1133

  Working, Peter K ^a   Newman, Mary S ^b   Sullivan, Timothy ^b   Yarrington, John ^b  

^a ALZA CORPORATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL TISSUE; CARDIOTOXICITY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG FORMULATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOGS; DOXORUBICIN; DRUG CARRIERS; DRUG COMPOUNDING; EXCIPIENTS; FEMALE; HEART DISEASES; LIPOSOMES; MALE; MYOCARDIUM; RABBITS;

EID: 0032925683     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Amantea MA, Newman MS, Sullivan TM, Forrest A and Working PK (1998) Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs. Hum Exp Toxicol 18:17-26.
2. Batist G, Winer E, Navari R, Rovira D and Azarnia N (1998) Decreased cardiac toxicity by TLC D-99 (liposome encapsulated doxorubicin) vs. doxorubicin in a randomized trial of metastatic breast carcinoma (Abstract). Proc Am Soc Clin Oncol 17:443.
3. Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, Patek A and Martin FJ (1998) The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 9:711-716.
4. Chlebowski RT, Paroly WS, Pugh RP, Hueser J, Jacobs EM, Pajak TF and Bateman JR (1980) Adriamycin given on a weekly schedule without a loading course: Clinically effective with a reduced incidence of cardiotoxicity. Cancer Treat Rep 64:47-51.
5. Dantchev D, Slioussartchouck V, Paintrand M, Hayat M, Bourout C and Mathe G (1979) Electron microscopy studies of heart and light microscopic studies of the skin after treatment of Golden hamsters with Adriamycin, detrorubicin, D-32 and Aclacinomycin. Cancer Treat Rep 63:875-888.
6. Doroshow JH, Tallent C and Schechter JE (1985) Ultrastructural features of Adriamyacin-induced skeletal and cardiac muscle toxicity. Am J Pathol 118:288-297.
7. Engbers CE, Newman MS and Working PK (1995) Blood and tissue distribution of doxorubicin in C26 tumor-bearing mice after treatment with either DOX-SL or Adriamycin. Proceedings of the American Association of Pharmaceutical Sciences, Western Regional Meeting, Abstract 3, p 20.
8. Forssen EA and Tokes ZA (1981) Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. Proc Natl Acad Sci USA 78:1873-1877.
9. Gabizon A, Barenholz Y and Bialer M (1993) Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol derivatized phospholipid: Pharmacokinetic studies in rodents and dogs. Pharm Res 10:703-708.
10. Gabizon A, Catane R, Uziely B, Kaufman B, Safra R, Cohen R, Martin F, Huang A and Barenholz Y (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol-coated liposomes. Cancer Res 54:987-992.
11. Gabizon A, Dagan A, Goren D, Barenholz Y and Fuks Z (1982) Liposomes as in vivo carriers of Adriamycin: Reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res 42:4734-4739.
12. Gottlieb JA, Lefrak EA, O'Brien PM and Burgess MA (1973) Fatal adriamycin cardiomyopathy: Prevention by dose limitation (Abstract). Proc Am Assoc Cancer Res 14:88.
13. Harris L, Winer E, Batist G, Rovira D, Navari R and Lee L (1998) Phase III study of TLC D-99 (liposome encapsulated doxorubicin) vs. free doxorubicin (Dox) in patients with metastatic breast carcinoma (Abstract). Proc An Soc Clin Oncol 17:474.
14. Herman EH, Rahman A, Ferrans VJ, Vick JA and Schein PS (1983) Prevention of chronic doxorubicin cardiotoxicity in beagles by liposome encapsulation. Cancer Res 43:5427-5732.
15. Iatropoulos MJ (1984) Anthracycline cardiomyopathy: Predictive value of animal models. Cancer Treat Symp 3:3-17.
16. Jaenke RS (1974) An anthracycline-induced cardiomyopathy in rabbits. Lab Invest 30:292-304.
17. Jaenke RS (1976) Delayed and progressive myocardial lesions after Adriamycin administration in the rabbit. Cancer Res 36:2958-2966.
18. Kanter PM, Bullard GA, Pilkiewicz FG, Mayer LD, Cullis PR and Pavelic ZP (1993) Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): Comparison with doxorubicin and empty liposomes in mice and dogs. In Vivo 7:85-95.
19. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdvieso M, Rasmussen SL, Blumenschein GR and Freireich E (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Int Med 96:133-139.
20. Lokich JJ and Moore C (1984) Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Int Med 101:798-799.
21. Mayer LD, Tai LCL and Ko DSC (1989) Influence of vesicle size, lipid composition and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 49:5922-5930.
22. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ and Liang L-J (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993.
23. Northfelt DW, Martin FJ, Working P, Volberding P, Russel J, Newman MS, Amantea M and Kaplan LD (1996) Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 36:55-63.
24. Olson RD and Mushlin PS (1990) Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEB J 4:3076-3086.
25. Pacciarini MA, Barbieri B, Colombo T, Broggini M, Garattini S and Donelli MG (1978) Distribution and antitumor activity of adriamycin in mice given in a high-dose and repeated low-dose schedule. Cancer Treat Rep 62:791-800.
26. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C and Martin FJ (1991) Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88:11460-11464.
27. Ranson M, Carmichael J, O'Bryne K, Stewart S, Smith D and Howell A (1997) Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial. J Clin Oncol 15:3185-3191.
28. Shenasa H, Calderone A, Vermeulen M, Paradis P, Stephens H, Cardinal R, de Champlain J and Rouleau JL (1990) Chronic doxorubicin induced cardiomyopathy in rabbits: Mechanical, intracellular action potential and β adrenergic characteristics of the failing myocardium. Cardiovasc Res 24:591-604.
29. Smith IE, Walsh G, Jones A, Prendiville J, Johnston S, Gusterson F, Ramage H, Robershaw H, Sacks N, Ebbs S, McKinna JA and Baum M (1996) High complete remission rates with primary neoadjuvant infusional chemotherapy. J Clin Oncol 13:424-429.
30. Speth PA, van Hoesel QGCM and Haanen C (1988) Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 15:15-31.
31. Steinherz U, Steinherz PG, Tan CT, Heller G and Murphy ML (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672-1677.
32. Vaage J, Barbera-Guillem E, Abra RA, Huang A and Working PK (1994) Tissue distributions and therapeutic effects of intravenous free or encapsulated liposomal doxorubicin on human prostatic carcinoma xenografts. Cancer 73:1478-1484.
33. Vaage J, Mayhew E, Lasic DD and Martin F (1992) Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long-circulating liposomes. Int J Cancer 51:942-948.
34. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ and Obradovich JE (1998) Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin-containing pegylated (Stealth) liposomes: A randomized, double-blind clinical trial using a canine model. Clin Cancer Res 4:1567-1571.
35. Van Vleet JF and Ferrans VJ (1986) Myocardial diseases of animals. Am J Pathol 124:95-178.
36. Vogelzang NJ and Ratain MJ (1985) Cancer chemotherapy and skin changes. Ann Int Med 103:303-304.
37. Weiss AJ, Metter GE, Fletcher WS, Wilson WL, Grage TB and Ramirez G (1976) Studies on Adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 60:813-822.
38. Working PK and Dayan AD (1996) Pharmacological-toxicological expert report. CAELYX (Stealth liposomal doxorubicin HCl). Human Exp Toxicol 15:752-785.
39. Working PK, Newman MS, Carter JL, Kerl RE and Kiorpes AL (1994a) Comparative target organ toxicity of free and liposome-encapsulated doxorubicin in rats. Toxicologist 14:217.
40. Working PK, Newman MS, Huang SK, Mayhew E, Vaage J and Lasic DD (1994b) Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth liposomes (DOXIL). J Lipo Res 4:667-687.